Dermavant’s Vtama Appears Well Positioned To Compete With Other Topicals In AD

 
• By Joseph Haas

Approved for psoriasis, Vtama met the primary and secondary endpoints in first of two Phase III atopic dermatitis studies. The Roivant affiliate will position the drug as a two-in-one solution for both.

Topical dermatology
Dermavant is working toward adding atopic dermatitis to Vtama's label • Source: Shutterstock

More from Strategy

More from Business